SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Update: AbbVie headquarters building in California
Earnings
AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira
AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance demonstrated the overall strength of its immunology franchise.
October 31, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Amgen's office in Massachusetts/iStock,
Pipeline
Amgen Whets Investors’ Appetites for MariTide Obesity Data by End of Year
While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on the highly anticipated MariTide Phase II results slated for late 2024, according to BMO Capital Markets analyst Evan Seigerman.
October 31, 2024
 · 
2 min read
 · 
Tristan Manalac
Image showing college students in lab looking through microscopes
Career Advice
Breaking Into Biotech: What You Must Know to Enter Industry
Candidates looking to enter biotech should focus on cultivating key skills, thoughtfully crafting their resumes and putting their best, most authentic foot forward in interviews. An internship, co-op or fellowship won’t hurt, either.
October 31, 2024
 · 
6 min read
 · 
Angela Gabriel
Novo Nordisk's logo on the facade of its building in Germany
GLP-1
FDA Says All Doses of Novo’s Ozempic, Wegovy Now Available
Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up with demand for the blockbuster GLP-1 drugs.
October 31, 2024
 · 
2 min read
 · 
Tristan Manalac
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
 · 
1 min read
 · 
Angela Gabriel
Biogen’s headquarters in Massachusetts
Earnings
Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal
Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.
October 30, 2024
 · 
2 min read
 · 
Heather McKenzie
Pictured: Eli Lilly's biotechnology center in California
Earnings
Lilly Hit With Lower-Than-Expected Mounjaro and Zepbound Q3 Sales, Narrows Full-Year Forecast
Eli Lilly’s blockbuster weight loss and diabetes drugs missed analysts’ expectations by 18% in the third quarter, which were negatively impacted by inventory stocking in the wholesaler channel. The company’s shares fell more than 13% in trading on Wednesday morning.
October 30, 2024
 · 
2 min read
 · 
Tristan Manalac
Earnings
Sage Touts Q3 Zurzuvae Revenue Growth, Will Not Seek MDD Indication
On its third-quarter earnings call Tuesday, Sage highlighted the launch of its Biogen-partnered postpartum depression drug Zurzuvae but said it will stop pursuing approval for major depressive disorder, which the FDA previously denied.
October 30, 2024
 · 
2 min read
 · 
Heather McKenzie
Pictured: BioMarin headquarters in California/iSto
Earnings
BioMarin Surpasses Analysts’ Q3 Sales Estimates Despite Voxzogo’s Slight Miss
The biotech beat Wall Street’s third-quarter revenue forecast by 6%, driven by increased uptake of its achondroplasia drug Voxzogo. However, William Blair downgraded BioMarin’s shares to market perform due to a “lack of near-term catalysts” and uncertainty around Voxzogo’s potential revenue growth.
October 30, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS